Evotec signs fourth translational research agreement with Sanofi

By Maggie Lynch

- Last updated on GMT

(Image :Getty/Shironosov)
(Image :Getty/Shironosov)

Related tags Evotec Sanofi Partnership Research Research and development Translational medicine

Evotec established an agreement with Sanofi to collaborate with academic institutions worldwide on early-stage translational projects.

The collaboration, Bridge Lab031, gives Evotec access to resources that can be used over the next three years while the companies focus on generating small molecules programs.

Evotec and Sanofi have worked together previously to support academic research through its Bridge programs. Lab031, the name referring to departmental code at University of Toulouse where Sanofi and Evotec started its partnership, will allow Evotec to validate translational ideas quickly by supporting more global initiatives.

Per the agreement, Evotec will use its discovery technologies to facilitate drug discovery and development more efficiently. Sanofi will have the option to take on development responsibility of each project upon milestone achievement.

The Bridge initiatives were established by the two companies as a way to combine academic research, biotechnology, and capital into the pharmaceutical industry. The initiatives were designed to accelerate translational projects from formulation across pre-clinical or proof-of-concept stages.

Three other Bridge initiatives have been created, Lab282, Lab150, and Lab591, each of which worked to set up researchers with affiliated hospitals and universities.

Sanofi and Evotec have been in exclusive partnerships outside the Bridge initiatives. The two companies recently signed a $74m agreement​ as part of which Evotec took on Sanofi’s infectious disease unit​ to develop new anti-infectives.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more